Limitations For limitations of use for specific ESAs, please see the FDA drug label. These cells are then released from the bone marrow into the bloodstream. 1 The FDA emphasized there should be a paradigm shift from aiming for a hemoglobin (Hgb) target range of 10 to 12 g/dL to using … They are given by injection. These drugs are given by injection (shot) and work by stimulating the production of more red blood cells. A blood transfusion is a procedure in which blood from a donor is … They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. Treatments for anemia may include iron, vitamin B 12, blood transfusion, or erythropoiesis–stimulating agents (ESAs).
In these situations they decrease the need for blood transfusions. The FDA has issued a black box warning for ESAs. Recombinant erythropoietin drugs are known as erythropoietin-stimulating agents (ESAs). Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. On June 24 the U.S. Food and Drug Administration (FDA) made a major modification to the erythropoiesis stimulating agent (ESA) label, recommending fundamental changes to how ESAs are used to manage chronic kidney disease (CKD) anemia (Table I). Epoetin beta is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis and patients not on dialysis. There are several causes of anemia, and its treatment will depend on its cause. The different agents are more or less equivalent.
